# Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

> **NCT00704691** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 1 (actual)

## Conditions studied

- Peripheral T-cell Lymphomas
- Adult T-cell Leukemia
- Adult T-cell Lymphoma
- Peripheral T-cell Lymphoma Unspecified
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- T/Null Cell Systemic Type
- Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00704691
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Closed due to futility with only 1 patient accrued
- **Last updated:** 2012-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704691, "Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00704691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*